Salarius Depreciation vs Begin Period Cash Flow Analysis

SLRX Stock  USD 1.52  0.15  10.95%   
Salarius Pharmaceuticals financial indicator trend analysis is much more than just breaking down Salarius Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Salarius Pharmaceuticals is a good investment. Please check the relationship between Salarius Pharmaceuticals Depreciation and its Begin Period Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Salarius Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Salarius Stock please use our How to Invest in Salarius Pharmaceuticals guide.

Depreciation vs Begin Period Cash Flow

Depreciation vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Salarius Pharmaceuticals Depreciation account and Begin Period Cash Flow. At this time, the significance of the direction appears to have weak relationship.
The correlation between Salarius Pharmaceuticals' Depreciation and Begin Period Cash Flow is 0.32. Overlapping area represents the amount of variation of Depreciation that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Salarius Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Salarius Pharmaceuticals' Depreciation and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation of Salarius Pharmaceuticals are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Depreciation i.e., Salarius Pharmaceuticals' Depreciation and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.32
Relationship DirectionPositive 
Relationship StrengthVery Weak

Depreciation

Depreciation indicates how much of Salarius Pharmaceuticals value has been used up. For tax purposes Salarius Pharmaceuticals can deduct the cost of the tangible assets it purchases as business expenses. However, Salarius Pharmaceuticals must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.
Most indicators from Salarius Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Salarius Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Salarius Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Salarius Stock please use our How to Invest in Salarius Pharmaceuticals guide.Issuance Of Capital Stock is likely to rise to about 10.1 M in 2024, whereas Selling General Administrative is likely to drop 5,435 in 2024.
 2023 2024 (projected)
Depreciation And Amortization10.059.55
Interest Income355.8K441.7K

Salarius Pharmaceuticals fundamental ratios Correlations

0.360.130.740.75-0.870.240.390.87-0.07-0.360.98-0.140.090.21-0.130.110.750.990.260.460.11-0.35-0.510.520.43
0.360.010.43-0.01-0.470.04-0.020.47-0.15-0.610.370.17-0.180.16-0.16-0.19-0.010.38-0.020.250.03-0.280.07-0.060.09
0.130.010.510.470.22-0.430.91-0.220.07-0.420.10.45-0.640.720.57-0.590.480.120.26-0.61-0.090.640.03-0.160.09
0.740.430.510.71-0.41-0.250.580.410.1-0.70.690.45-0.610.690.39-0.580.720.710.56-0.20.20.25-0.10.060.16
0.75-0.010.470.71-0.43-0.260.710.43-0.32-0.450.780.02-0.180.280.39-0.141.00.780.16-0.04-0.230.13-0.450.580.27
-0.87-0.470.22-0.41-0.43-0.43-0.07-1.00.180.16-0.890.38-0.440.160.44-0.45-0.42-0.88-0.05-0.8-0.140.720.49-0.6-0.4
0.240.04-0.43-0.25-0.26-0.43-0.410.440.40.410.17-0.620.66-0.16-0.940.65-0.280.17-0.230.720.12-0.68-0.3-0.050.31
0.39-0.020.910.580.71-0.07-0.410.07-0.08-0.380.370.3-0.440.510.55-0.380.710.390.3-0.4-0.090.48-0.270.230.34
0.870.47-0.220.410.43-1.00.440.07-0.18-0.160.89-0.380.44-0.16-0.450.450.420.880.050.80.14-0.72-0.50.590.41
-0.07-0.150.070.1-0.320.180.4-0.08-0.180.28-0.240.12-0.220.45-0.19-0.23-0.33-0.230.58-0.20.620.28-0.05-0.550.25
-0.36-0.61-0.42-0.7-0.450.160.41-0.38-0.160.28-0.38-0.40.6-0.45-0.340.59-0.46-0.4-0.010.240.39-0.19-0.090.020.16
0.980.370.10.690.78-0.890.170.370.89-0.24-0.38-0.180.140.11-0.10.170.781.00.150.490.01-0.4-0.490.610.37
-0.140.170.450.450.020.38-0.620.3-0.380.12-0.4-0.18-0.840.570.69-0.840.04-0.160.56-0.710.290.620.6-0.49-0.25
0.09-0.18-0.64-0.61-0.18-0.440.66-0.440.44-0.220.60.14-0.84-0.78-0.751.0-0.20.12-0.520.85-0.14-0.81-0.430.510.26
0.210.160.720.690.280.16-0.160.51-0.160.45-0.450.110.57-0.780.36-0.760.30.140.48-0.560.250.560.32-0.58-0.15
-0.13-0.160.570.390.390.44-0.940.55-0.45-0.19-0.34-0.10.69-0.750.36-0.740.4-0.10.43-0.820.030.820.25-0.02-0.19
0.11-0.19-0.59-0.58-0.14-0.450.65-0.380.45-0.230.590.17-0.841.0-0.76-0.74-0.160.15-0.520.84-0.15-0.8-0.470.540.29
0.75-0.010.480.721.0-0.42-0.280.710.42-0.33-0.460.780.04-0.20.30.4-0.160.780.17-0.05-0.220.14-0.420.560.25
0.990.380.120.710.78-0.880.170.390.88-0.23-0.41.0-0.160.120.14-0.10.150.780.160.480.01-0.39-0.490.60.38
0.26-0.020.260.560.16-0.05-0.230.30.050.58-0.010.150.56-0.520.480.43-0.520.170.16-0.360.80.45-0.01-0.140.22
0.460.25-0.61-0.2-0.04-0.80.72-0.40.8-0.20.240.49-0.710.85-0.56-0.820.84-0.050.48-0.36-0.02-0.97-0.410.50.26
0.110.03-0.090.2-0.23-0.140.12-0.090.140.620.390.010.29-0.140.250.03-0.15-0.220.010.8-0.020.090.13-0.250.18
-0.35-0.280.640.250.130.72-0.680.48-0.720.28-0.19-0.40.62-0.810.560.82-0.80.14-0.390.45-0.970.090.21-0.38-0.07
-0.510.070.03-0.1-0.450.49-0.3-0.27-0.5-0.05-0.09-0.490.6-0.430.320.25-0.47-0.42-0.49-0.01-0.410.130.21-0.73-0.81
0.52-0.06-0.160.060.58-0.6-0.050.230.59-0.550.020.61-0.490.51-0.58-0.020.540.560.6-0.140.5-0.25-0.38-0.730.45
0.430.090.090.160.27-0.40.310.340.410.250.160.37-0.250.26-0.15-0.190.290.250.380.220.260.18-0.07-0.810.45
Click cells to compare fundamentals

Salarius Pharmaceuticals Account Relationship Matchups

Salarius Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets13.9M24.9M40.8M14.7M6.6M6.3M
Other Current Liab478.5K442.3K567.8K1.4M406.7K532.5K
Total Current Liabilities3.3M2.8M2.1M4.3M1.3M2.3M
Total Stockholder Equity10.6M22.2M38.7M10.4M5.3M5.0M
Property Plant And Equipment Net74K25.0K22.6K7.9K7.1K6.7K
Net Debt(3.2M)(10.6M)(29.2M)(12.1M)(5.6M)(5.9M)
Retained Earnings(12.1M)(19.4M)(32.2M)(63.8M)(76.3M)(80.2M)
Accounts Payable1.8M1.9M1.5M2.9M602.9K572.7K
Cash3.7M11.1M29.2M12.1M5.9M5.6M
Non Current Assets Total9.2M9.1M10.7M130.5K66.9K63.5K
Non Currrent Assets Other308.7K247.1K1.8M130.5K66.9K63.5K
Cash And Short Term Investments3.7M11.1M29.2M12.1M5.9M5.6M
Common Stock Total Equity1.8K1.8K451.02.4K2.7K1.6K
Liabilities And Stockholders Equity13.9M24.9M40.8M14.7M6.6M6.3M
Non Current Liabilities Total980.9K919.4K567.8K1.4M406.7K386.4K
Other Current Assets955.9K822.1K949.2K803.4K619.8K816.3K
Other Stockholder Equity22.7M41.6M70.9M74.2M81.6M82.0M
Total Liab3.3M2.8M2.1M4.3M1.3M1.2M
Property Plant And Equipment Gross331.0K74.5K25.0K22.6K20.4K19.4K
Total Current Assets4.7M15.8M30.2M14.5M6.5M6.2M
Common Stock451.02.4K4.5K225.0393.0373.35
Net Tangible Assets1.7M13.3M29.9M10.4M9.3M14.2M
Other Assets0.0247.1K1.8M130.5K1.00.95
Common Stock Shares Outstanding130.7K623.1K1.7M2.1M3.3M3.4M
Capital Surpluse140.2M142.2M22.7M41.6M37.4M35.6M
Property Plant Equipment37.5K25.0K22.6K7.9K7.1K6.7K
Inventory432K187K0.0(1.6M)(1.4M)(1.4M)
Net Invested Capital11.1M22.6M38.7M10.4M5.6M5.3M
Net Working Capital1.4M13.0M28.1M10.3M5.2M5.0M
Capital Stock451.02.4K4.5K225.0393.0373.35

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Salarius Stock Analysis

When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.